The shares of The E.W. Scripps Company (NASDAQ:SSP) has been pegged with a rating of Buy by The Benchmark Company in its latest research note that was published on November 11, 2019. The Services company has also assigned a $24 price target. The Benchmark Company wasn’t the only research firm that published a report of The E.W. Scripps Company, with other equities research analysts also giving their opinion on the stock. The Benchmark Company advised investors in its research note published on March 04, 2019, to Buy the SSP stock while also putting a $26 price target. The stock had earned Buy rating from Gabelli & Co Markets when it published its report on November 27, 2018. The stock was given Buy rating by The Benchmark Company in its report released on November 06, 2017, the day when the price target on the stock was placed at 20. Guggenheim was of a view that SSP is Neutral in its latest report on October 18, 2017. The Benchmark Company thinks that SSP is worth Buy rating. This was contained in the firm’s report on March 27, 2017 in which the stock’s price target was also moved to 26.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 2 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Overweight while its average price target is $17.60. The price of the stock the last time has raised by 28.87% from its 52-Week high price while it is -62.40% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 41.75.
The shares of the company added by 12.76% during the trading session on Wednesday, reaching a low of $7.37 while ending the day at $8.75. During the trading session, a total of 543066.0 shares were traded which represents a -37.02% decline from the average session volume which is 396330.0 shares. SSP had ended its last session trading at $7.76. The E.W. Scripps Company debt-to-equity ratio currently stands at 2.13, while its quick ratio hovers at 1.90 SSP 52-week low price stands at $6.79 while its 52-week high price is $23.27.
The The E.W. Scripps Company generated 32.97 million in revenue during the last quarter. In the second quarter last year, the firm recorded -$0.11 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 125.0%. The E.W. Scripps Company has the potential to record 1.69 EPS for the current fiscal year, according to equities analysts.
Investment analysts at RBC Capital Mkts published a research note on March 13, 2020 where it informed investors and clients that Inovio Pharmaceuticals Inc. (NASDAQ:INO) is now rated as Sector Perform. Even though the stock has been trading at $7.09/share, analysts expect it to down by -5.78% to reach $10.43/share. It started the day trading at $6.95 and traded between $6.57 and $6.68 throughout the trading session.
A look at its technical shows that INO’s 50-day SMA is 5.25 while its 200-day SMA stands at 3.24. The stock has a high of $19.36 for the year while the low is $1.91. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 16.15 M shorted shares, the short percentage went higher by 33.77%, as 21.60M SSP shares were shorted. At the moment, only 11.47% of Inovio Pharmaceuticals Inc. shares were sold short. The company’s average trading volume currently stands at 26.94M shares, which means that the short-interest ratio is just 0.60 days. Over the past seven days, the company moved, with its shift of -10.22%. Looking further, the stock has raised 79.57% over the past 90 days while it gained 205.02% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Wasatch Advisors, Inc. bought more INO shares, increasing its portfolio by 12.65% during the last quarter. This move now sees The Wasatch Advisors, Inc. purchasing 840,281 shares in the last quarter, thus it now holds 7,482,827 shares of INO, with a total valuation of $32,026,500. BlackRock Fund Advisors meanwhile sold more INO shares in the recently filed quarter, changing its stake to $30,350,738 worth of shares.
Similarly, Nikko Asset Management Americas, … decreased its Inovio Pharmaceuticals Inc. shares by 2.11% during the recently filed quarter. After selling 5,047,608 shares in the last quarter, the firm now controls -108,742 shares of Inovio Pharmaceuticals Inc. which are valued at $21,603,762. In the same vein, Nikko Asset Management Co., Ltd. decreased its Inovio Pharmaceuticals Inc. shares by during the most recent reported quarter. The firm sold 108,742 shares during the quarter which decreased its stakes to 5,047,608 shares and is now valued at $21,603,762. Following these latest developments, around 1.60% of Inovio Pharmaceuticals Inc. stocks are owned by institutional investors and hedge funds.